COMPARE THE THREE
How Strong Is the Proof for Each Peptide?
Compare the study groups, the measured changes, approved uses, and remaining risks when your own health may differ.
What is the quickest fair comparison?
Large human trials give semaglutide the broadest record by far. The studies cover weight, diabetes, heart disease, and kidney disease.
Tesamorelin has one well-tested use in adults with HIV. FDA clearance for that use does not prove broad weight loss.
MOTS-c has no finished trial in which people received it. Almost all claims come from mice and cells.
All three appear in research about body fuel and weight. That shared subject doesn’t mean each peptide has equally firm proof.
This page compares the people tested, approved uses, and main cautions. It doesn’t offer a dose or personal medical advice.
What does a side-by-side check show?
| Question | MOTS-c | Semaglutide | Tesamorelin |
|---|---|---|---|
| What does it act like? | A peptide made from DNA in cell parts that produce energy | The GLP-1 gut hormone, which aids sugar control and fullness | A hormone that asks the growth gland to work |
| What human proof exists? | No finished trial giving it to people; one study measured natural blood levels [2] | Large trials in tens of thousands of people [6][7][8][9][12] | Trials with several hundred adults in one HIV-related group [13][15][17] |
| What was studied most? | Mouse muscle, exercise, aging, and cells | Type 2 diabetes, obesity, heart health, and kidney health | Deep belly fat and fat stored in the liver from an HIV-related disorder |
| How was it given in studies? | Only animal amounts are known [3] | A shot each week or one tablet each day | A daily shot under the skin |
| Does it have FDA approval? | No; sold only as a lab chemical | Approved for several uses | Approved for one HIV-related fat disorder |
| What is the main caution? | Human benefits, harms, and amounts remain unknown [3] | Stomach, gallbladder, eye, and thyroid warnings [10][12] | Fat returns after stopping; other groups lack equal proof [17] |
Do the three peptides work the same way?
Semaglutide copies the GLP-1 gut hormone, which helps with insulin, hunger, and stomach emptying [11]. That is why it affects blood sugar and how much people eat.
Tesamorelin asks the growth gland to send out hormone in short bursts [16]. The liver then makes IGF-1, a protein that helps break down deep belly fat.
MOTS-c attaches to a protein called casein kinase 2, which controls some cell work [1]. In mice, the tie helped muscle stay strong and take in sugar.
The three routes aren’t alike. Their shared subject is body fuel and weight, not one shared way of working.
How many people were studied?
Semaglutide trials ranged from roughly 2,000 to more than 17,000 people. They measured weight, heart problems, kidney problems, and direct drug results [6][7][8][9][12].
Tesamorelin trials included several hundred adults from one HIV-related group. A much smaller study also tested healthy men [13][15][16][17].
The lone MOTS-c human study followed 94 dialysis patients [2]. It measured MOTS-c already in their blood and didn’t give them treatment.
That is the widest gap among the three. Claims about MOTS-c in people still depend on mouse and cell work.
Why does semaglutide have several approvals, while tesamorelin has one?
Semaglutide and tesamorelin are both FDA-approved, but at very different scales. Semaglutide carries approvals spanning type 2 diabetes, chronic weight management, cardiovascular-risk reduction, and (as of 2025) metabolic liver disease. Tesamorelin carries exactly one approval — reducing excess visceral fat in HIV-associated lipodystrophy [14] — and no other indication. MOTS-c has no regulatory approval of any kind and is sold exclusively as a research chemical, with supplier-dependent purity and identity that is not subject to pharmaceutical oversight. Approval status is not a proxy for how broadly a compound's evidence generalizes; tesamorelin's single approval is narrower than casual references to it as an 'approved peptide' tend to suggest.
Prescription status is also access status. In the United States, an approved peptide medicine reaches a patient through a licensed prescriber — increasingly via telehealth, where providers such as Promise Peptides (mypromise.com) run a doctor-guided model: a clinician evaluates the patient and sets the protocol, rather than the buyer selecting a compound from a catalog. A research chemical travels no such route — no prescriber, no pharmacy, no regulated manufacturing behind it — which is why 'available online' can describe both channels while meaning very different things about oversight.
What is the main caution for each one?
Semaglutide has strong benefit data and several known harms. Nausea, gallbladder trouble, an eye risk, and a thyroid warning all deserve careful attention [10][12].
Tesamorelin’s main limit is the narrow group studied in its trials. Its fat loss reverses after stopping, and other groups lack equal trials [17].
MOTS-c has the largest and most basic unknown. No human trial has produced sound benefit, harm, or dose facts [3].
The fair comparison is not simply safe against risky. It is how much your doctor can know from human studies before helping you choose.